

Merit E Cudkowicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5781784/publications.pdf>

Version: 2024-02-01

117
papers

9,091
citations

66234

42
h-index

45213

90
g-index

124
all docs

124
docs citations

124
times ranked

10338
citing authors

#	ARTICLE	IF	CITATIONS
1	ALSUntangled #63: ketogenic diets. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 159-163.	1.1	3
2	Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 66-75.	1.1	1
3	Novel genetic variants in <i>MAPT</i> and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Brain Pathology, 2022, 32, e13035.	2.1	15
4	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2022, 59, 683-702.	1.9	18
5	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.5	51
6	A Phase 1 study of <i>GDC-0134</i> , a dual leucine zipper kinase inhibitor, in <i>ALS</i> . Annals of Clinical and Translational Neurology, 2022, 9, 50-66.	1.7	20
7	A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, 65, 291-302.	1.0	41
8	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology, 2022, 91, 165-175.	2.8	41
9	Phase 2B randomized controlled trial of <i>NP001</i> in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	1.0	16
10	Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience, 2022, 25, 226-237.	7.1	66
11	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.4	1
12	ALSUntangled #64: butyrates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 638-643.	1.1	6
13	Regulatory Approval in ALS; When Is a Single Study Enough?. Annals of Neurology, 2022, 91, 737-739.	2.8	4
14	Survival analyses from the <i>CENTAUR</i> trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. Muscle and Nerve, 2022, 66, 136-141.	1.0	30
15	Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the <i>CENTAUR</i> trial. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 871-875.	0.9	37
16	An expanded access protocol of <i>RT001</i> in amyotrophic lateral sclerosis—Initial experience with a lipid peroxidation inhibitor. Muscle and Nerve, 2022, 66, 421-425.	1.0	10
17	Long-term survival of participants in the <i>CENTAUR</i> trial of sodium phenylbutyrate- <i>taurursodiol</i> in amyotrophic lateral sclerosis. Muscle and Nerve, 2021, 63, 31-39.	1.0	115
18	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79

#	ARTICLE	IF	CITATIONS
19	Improving clinical trial outcomes in amyotrophic lateral sclerosis. <i>Nature Reviews Neurology</i> , 2021, 17, 104-118.	4.9	152
20	lbudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. <i>NeuroImage: Clinical</i> , 2021, 30, 102672.	1.4	21
21	Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD. <i>Brain Imaging and Behavior</i> , 2021, 15, 2540-2551.	1.1	9
22	Noninvasive ventilation use by patients enrolled in VITALITY-ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 1-9.	1.1	0
23	Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. <i>Muscle and Nerve</i> , 2021, 64, 309-320.	1.0	27
24	Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	27
25	Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment. <i>Muscle and Nerve</i> , 2021, 64, 532-537.	1.0	16
26	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831.	4.9	9
27	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. <i>Muscle and Nerve</i> , 2021, 63, 371-383.	1.0	13
28	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. <i>Neurology: Clinical Practice</i> , 2021, 11, e472-e479.	0.8	0
29	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 15-23.	1.1	12
30	Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. <i>Muscle and Nerve</i> , 2020, 62, 156-166.	1.0	60
31	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients A Randomized Phase 2 Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3682.	1.0	15
32	Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. <i>Frontiers in Neurology</i> , 2020, 11, 590573.	1.1	16
33	Trial of Sodium Phenylbutyrate Taurursodiol for Amyotrophic Lateral Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 919-930.	13.9	299
34	Phase 1 2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. <i>New England Journal of Medicine</i> , 2020, 383, 109-119.	13.9	354
35	ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 216-221.	1.1	5
36	Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2020, 9, 47-58.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€œSupported Network for Excellence in Neuroscience Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 755.	4.5	6
38	Amyotrophic lateral sclerosis care and research in the United States during the <sc>COVID</sc>â€œ19 pandemic: Challenges and opportunities. <i>Muscle and Nerve</i> , 2020, 62, 182-186.	1.0	42
39	Preface: promoting research in PLS: current knowledge and future challenges. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 1-2.	1.1	6
40	ALS/SURV: a modification of the CAFS statistic. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 576-583.	1.1	2
41	Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkers. <i>Neurology</i> , 2019, 93, e1605-e1617.	1.5	29
42	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach. <i>Scientific Reports</i> , 2019, 9, 690.	1.6	46
43	Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. <i>BMC Neurology</i> , 2019, 19, 104.	0.8	13
44	A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 584-594.	1.1	29
45	Risk factors for suicidality in Huntington disease. <i>Neurology</i> , 2019, 92, e1643-e1651.	1.5	22
46	Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2019, 9, 17728.	1.6	26
47	NurOwn, phase 2, randomized, clinical trial in patients with ALS. <i>Neurology</i> , 2019, 93, e2294-e2305.	1.5	95
48	Final Results of the RHAPSODY Trial: A Multiâ€œCenter, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€œAPC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. <i>Annals of Neurology</i> , 2019, 85, 125-136.	2.8	113
49	A pilot trial of RNS60 in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2019, 59, 303-308.	1.0	29
50	Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, doubleâ€œblind crossover trial. <i>Muscle and Nerve</i> , 2018, 58, 42-48.	1.0	38
51	Understanding the use of NIV in ALS: results of an international ALS specialist survey. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 331-341.	1.1	31
52	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS. <i>Neurology</i> , 2018, 90, e565-e574.	1.5	99
53	VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 259-266.	1.1	21
54	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 242-249.	1.1	35

#	ARTICLE	IF	CITATIONS
55	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
56	Respiratory measures in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 321-330.	1.1	44
57	Imaging of glia activation in people with primary lateral sclerosis. <i>NeuroImage: Clinical</i> , 2018, 17, 347-353.	1.4	29
58	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. <i>Muscle and Nerve</i> , 2018, 57, 430-434.	1.0	39
59	A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 250-258.	1.1	44
60	Opinion and Special Articles: Challenges and opportunities in defining career identity in academic neurology. <i>Neurology</i> , 2018, 91, 670-672.	1.5	6
61	Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1522-1533.	1.7	31
62	Expanded autologous regulatory T-lymphocyte infusions in ALS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e465.	3.1	116
63	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. <i>EBioMedicine</i> , 2018, 33, 169-184.	2.7	17
64	Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!. <i>Contemporary Clinical Trials Communications</i> , 2018, 11, 113-119.	0.5	11
65	Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. <i>Journal of Clinical Investigation</i> , 2018, 128, 3558-3567.	3.9	171
66	Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. <i>Neurotherapeutics</i> , 2017, 14, 762-772.	2.1	73
67	Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. <i>Muscle and Nerve</i> , 2017, 56, 710-715.	1.0	15
68	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 99-105.	0.9	68
69	Developing multidisciplinary clinics for neuromuscular care and research. <i>Muscle and Nerve</i> , 2017, 56, 848-858.	1.0	38
70	Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2017, 56, 726-731.	1.0	22
71	Natural history of infantile-onset spinal muscular atrophy. <i>Annals of Neurology</i> , 2017, 82, 883-891.	2.8	276
72	Serum urate at trial entry and ALS progression in EMPOWER. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 120-125.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. <i>Journal of Huntington's Disease</i> , 2017, 6, 149-156.	0.9	0
74	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). <i>Journal of Neurology & Neurophysiology</i> , 2017, 08, .	0.1	17
75	The Role of Environmental Toxins in Amyotrophic Lateral Sclerosis Risk. <i>JAMA Neurology</i> , 2016, 73, 779.	4.5	5
76	Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. <i>Stroke</i> , 2016, 47, 2979-2985.	1.0	20
77	Quantitative strength testing in ALS clinical trials. <i>Neurology</i> , 2016, 87, 617-624.	1.5	37
78	Transplantation of spinal cordâ€derived neural stem cells for ALS. <i>Neurology</i> , 2016, 87, 392-400.	1.5	127
79	Race/ethnicity, socioeconomic status, and ALS mortality in the United States. <i>Neurology</i> , 2016, 87, 2300-2308.	1.5	37
80	Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. <i>Neurology</i> , 2016, 87, 2554-2561.	1.5	83
81	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. <i>Journal of Clinical Neuromuscular Disease</i> , 2016, 17, 99-105.	0.3	17
82	How common are ALS plateaus and reversals?. <i>Neurology</i> , 2016, 86, 808-812.	1.5	78
83	Job-related formaldehyde exposure and ALS mortality in the USA: TableÂ¹. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 786-788.	0.9	30
84	A randomized trial of mexiletine in ALS. <i>Neurology</i> , 2016, 86, 1474-1481.	1.5	72
85	Preclinical rodent toxicity studies for long term use of ceftriaxone. <i>Toxicology Reports</i> , 2015, 2, 1396-1403.	1.6	7
86	Reply. <i>Muscle and Nerve</i> , 2015, 52, 691-691.	1.0	2
87	Preâ€morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 52, 339-343.	1.0	25
88	Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. <i>NeuroImage: Clinical</i> , 2015, 7, 409-414.	1.4	176
89	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. <i>Nature Biotechnology</i> , 2015, 33, 51-57.	9.4	178
90	Randomized phase 2 trial of NPO01, a novel immune regulator. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e100.	3.1	83

#	ARTICLE	IF	CITATIONS
91	Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1235.	4.5	11
92	ISDN2014_0028: REMOVED: Targeting miRâ€155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. <i>International Journal of Developmental Neuroscience</i> , 2015, 47, 5-5.	0.7	1
93	Neuroprotective agents target molecular mechanisms of disease in ALS. <i>Drug Discovery Today</i> , 2015, 20, 65-75.	3.2	30
94	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e97803.	1.1	45
95	The PRO-ACT database. <i>Neurology</i> , 2014, 83, 1719-1725.	1.5	222
96	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 141.	4.5	211
97	Locked in, but not out?. <i>Neurology</i> , 2014, 82, 1852-1853.	1.5	17
98	Outcome measures in amyotrophic lateral sclerosis clinical trials. <i>Clinical Investigation</i> , 2014, 4, 605-618.	0.0	50
99	Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons. <i>Cell Reports</i> , 2014, 7, 1-11.	2.9	583
100	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 1083-1091.	4.9	187
101	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. <i>Neuron</i> , 2014, 83, 1043-1050.	3.8	289
102	Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet</i> , The, 2014, 383, 2065-2072.	6.3	233
103	Dexramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. <i>Lancet Neurology</i> , The, 2013, 12, 1059-1067.	4.9	216
104	The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 162-168.	1.1	88
105	The effects of dexramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. <i>Nature Medicine</i> , 2011, 17, 1652-1656.	15.2	166
106	A futility study of minocycline in Huntington's disease. <i>Movement Disorders</i> , 2010, 25, 2219-2224.	2.2	79
107	Toward more efficient clinical trials for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 259-265.	2.3	77
108	Phase 2 study of sodium phenylbutyrate in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 99-106.	2.3	135

#	ARTICLE	IF	CITATIONS
109	Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2008, 38, 837-844.	1.0	104
110	Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. <i>Journal of Neurochemistry</i> , 2006, 96, 908-908.	2.1	2
111	Trial of celecoxib in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2006, 60, 22-31.	2.8	276
112	Maximum voluntary isometric contraction (MVIC). <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2004, 5, 84-85.	1.4	11
113	Measures and markers in Amyotrophic Lateral Sclerosis. <i>NeuroRx</i> , 2004, 1, 273-283.	6.0	63
114	Measures and markers in Amyotrophic Lateral Sclerosis. <i>Neurotherapeutics</i> , 2004, 1, 273-283.	2.1	0
115	Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. <i>Journal of Applied Physiology</i> , 2000, 88, 2045-2053.	1.2	400
116	Gait variability and basal ganglia disorders: Stride-to-stride variations of gait cycle timing in parkinson's disease and Huntington's disease. <i>Movement Disorders</i> , 1998, 13, 428-437.	2.2	752
117	Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	32